Source: Eur Respir J 2012; 40: 792-793
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Hanf Matthieu, Adenis Antoine, Couppié Pierre, Carme Bernard, Nacher Mathieu. The impact of corruption on multidrug-resistant tuberculosis: a quantitative assessment},. Eur Respir J 2012; 40: 792-793

Member's Comments

No comment yet.

Related content which might interest you: Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 GenoType MTBDRsl performance on clinical samples with diverse genetic background}, Source: Eur Respir J 2012; 40: 690-698 Year: 2012 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis Source: Eur Respir J 2008; 32: 1165-1174 Year: 2008 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Quantitative scoring of an interferon-γ assay for differentiating active from latent tuberculosis Source: Eur Respir J 2007; 30: 722-728 Year: 2007 Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Multidrug-resistant tuberculosis in children: evidence from global surveillance Source: Eur Respir J 2013; 42: 701-707 Year: 2013 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 Correlation of Mycobacterium tuberculosis [not]-specific and non-specific quantitative T cell IFN-γ responses with mycobacillary load in a HIV-prevalent high burden setting Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Childhood tuberculosis: progress requires an advocacy strategy now Source: Eur Respir J 2012; 40: 294-297 Year: 2012 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Comparision of line probe assay and conventional methos for detection of mycobacteria other than tuberculosis (MOTT) strains from patients suferring from pulmonary tuberculosis Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies Source: Eur Respir J, 57 (4) 2004315; 10.1183/13993003.04315-2020 Year: 2021 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005